Literature DB >> 12383878

Increased expression of renal neutral endopeptidase in severe heart failure.

Mathias Knecht1, Ines Pagel, Thomas Langenickel, Sebastian Philipp, Michaela Scheuermann-Freestone, Thomas Willnow, Dennis Bruemmer, Kristof Graf, Rainer Dietz, Roland Willenbrock.   

Abstract

The enzyme neutral endopeptidase (NEP; EC 3.4.24.11) cleaves several vasoactive peptides such as the atrial natriuretic peptide (ANP). ANP is a hormone of cardiac origin with diuretic and natriuretic actions. Despite elevated circulating levels of ANP, congestive heart failure (CHF) is characterized by progressive sodium and water retention. In order to elucidate the loss of natriuretic and diuretic properties of ANP in CHF we analyzed activity, protein concentrations, mRNA and immunostaining of NEP in kidneys of different models of severe CHF in the rat.CHF was induced by either aortocaval shunt, aortic banding or myocardial infarction in the rat. All models were defined by increased left ventricular end-diastolic pressure and decreased contractility. The diminished effectiveness of ANP was reflected by reduced cGMP/ANP ratio in animals with shunt or infarction. Renal NEP activity was increased in rats with aortocaval shunt (203 +/- 7%, p < 0.001), aortic banding (184 +/- 11%, p < 0.001) and infarction (149 +/- 10%, p < 0.005). Western blot analysis revealed a significant increase in renal NEP protein content in two models of CHF (shunt: 214 +/- 57%, p < 0.05; infarction: 310 +/- 53 %, p < 0.01). The elevated protein expression was paralleled by a threefold increase in renal NEP-mRNA level in the infarction model. The increased renal NEP protein expression and activity may lead to enhanced degradation of ANP and may contribute to the decreased renal response to ANP in heart failure. Thus, the capacity to counteract sodium and water retention, would be diminished. The increased renal NEP activity may therefore be a hitherto unknown factor in the progression of CHF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383878     DOI: 10.1016/s0024-3205(02)01990-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

1.  Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?

Authors:  Naveen L Pereira; Viral K Desai; Allan S Jaffe
Journal:  Eur J Heart Fail       Date:  2019-03-04       Impact factor: 15.534

2.  Neonate with vein of Galen malformation and heart failure: serial changes in plasma B-type natriuretic peptide following endovascular embolization.

Authors:  L H Tan; B A Johnson; M E Mawad; A C Chang
Journal:  Pediatr Cardiol       Date:  2006-02-20       Impact factor: 1.655

3.  Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte.

Authors:  Deborah M Dickey; Daniel L Dries; Kenneth B Margulies; Lincoln R Potter
Journal:  J Mol Cell Cardiol       Date:  2011-11-22       Impact factor: 5.000

4.  Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

Authors:  Naveen L Pereira; Pinar Aksoy; Irene Moon; Yi Peng; Margaret M Redfield; John C Burnett; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum
Journal:  J Mol Cell Cardiol       Date:  2010-08-06       Impact factor: 5.000

Review 5.  Insights into natriuretic peptides in heart failure: an update.

Authors:  Josef Korinek; Guido Boerrigter; Selma F Mohammed; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2008-06

6.  A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation.

Authors:  Deborah M Dickey; Andrea R Yoder; Lincoln R Potter
Journal:  J Biol Chem       Date:  2009-05-19       Impact factor: 5.157

7.  New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027.

Authors:  Vijaya Arun Kumar; David Viau; Phillip Levy
Journal:  Curr Emerg Hosp Med Rep       Date:  2015-05-01

8.  Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis.

Authors:  C Moro; E Klimcakova; M Lafontan; M Berlan; J Galitzky
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

9.  The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure.

Authors:  Patrícia Lourenço; José Paulo Araújo; Ana Azevedo; António Ferreira; Paulo Bettencourt
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 10.  Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials.

Authors:  Bibhuti B Das; William B Moskowitz; Javed Butler
Journal:  Children (Basel)       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.